Kirsi Ketola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/710478/publications.pdf Version: 2024-02-01



KIDSI KETOLA

#	Article	IF	CITATIONS
1	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
2	High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth. Clinical Cancer Research, 2009, 15, 6070-6078.	3.2	185
3	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530.	0.8	152
4	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. British Journal of Cancer, 2012, 106, 99-106.	2.9	141
5	Using online game-based platforms to improve student performance and engagement in histology teaching. BMC Medical Education, 2019, 19, 273.	1.0	106
6	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. American Journal of Pathology, 2011, 178, 525-536.	1.9	102
7	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget, 2013, 4, 48-63.	0.8	95
8	PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma. Cancer Research, 2009, 69, 2870-2877.	0.4	80
9	Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 3175-3185.	1.9	80
10	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocrine-Related Cancer, 2015, 22, R165-R182.	1.6	52
11	Targeting Lyn regulates Snail family shuttling and inhibits metastasis. Oncogene, 2017, 36, 3964-3975.	2.6	33
12	Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. Clinical Cancer Research, 2017, 23, 6923-6933.	3.2	30
13	CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. Cells, 2019, 8, 276.	1.8	26
14	Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells. PLoS ONE, 2012, 7, e51470.	1.1	24
15	The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Molecular Cancer Research, 2019, 17, 2154-2168.	1.5	20
16	Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression. Cancers, 2021, 13, 692.	1.7	17
17	Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function. Frontiers in Physiology, 2019, 10, 224.	1.3	16
18	Thermal dose as a universal tool to evaluate nanoparticle-induced photothermal therapy. International Journal of Pharmaceutics, 2020, 587, 119657.	2.6	11

Kirsi Ketola

#	Article	IF	CITATIONS
19	BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation. Oncogene, 2020, 39, 2391-2407.	2.6	9
20	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. Journal of Molecular Biochemistry, 2016, 5, 12-22.	0.1	7
21	M1 Macrophages Induce Protumor Inflammation in Melanoma Cells through TNFR–NF-κB Signaling. Journal of Investigative Dermatology, 2022, 142, 3041-3051.e10.	0.3	7
22	Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Research, 2021, 81, 4901-4909.	0.4	6
23	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population. , 0, , .		2
24	The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts. Molecular and Translational Medicine, 2017, , 71-91.	0.4	0
25	Abstract A62: Monensin-induced oxidative stress reduces prostate cancer cell motility and cancer stem cell markers , 2011, , .		0
26	Abstract C91: Targeting enzalutamide resistance in prostate cancer , 2013, , .		0
27	Abstract 4106: Lyn kinase promotes metastasis through EMT in cancers. , 2015, , .		0
28	Abstract 1682: Lyn drives cancer metastasis via post-translational regulation of SNAI proteins. , 2016, , .		0
29	Abstract 3342: Galiellalactone derivative targets stem cell population in ENZ-resistant prostate cancer through inhibition of STAT3. , 2016, , .		0
30	Abstract 5025: EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer. , 2017, , .		0
31	Abstract 3189: Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer. , 2017, , .		Ο
32	Abstract 4995: Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy. , 2018, , .		0
33	Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy. , 2018. , .		0